Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Moderna

Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market

After COVID-19 vaccine-induced strength, Moderna, Inc. (NASDAQ: MRNA) is on the lookout for the next big catalyst to boost its rangebound stock.

Benzinga

The Future of Boosters Is Somewhere Between Unnecessary and Urgent

Until there’s a universal coronavirus vaccine, the future of additional shots is a murky work in progress—but more rounds seem increasingly likely.

Businessweek

The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Like Pfizer, Moderna Seeks FDA Approval For Fourth COVID-19 Shot Or Second Booster Dose

Moderna Inc (NASDAQ: MRNA) has asked the FDA to authorize a

Benzinga

Moderna Seeks US Approval of Second Covid Booster

Moderna announced Thursday it had asked the United States drug regulator for emergency authorization for a second booster shot of the company's Covid-19 vaccine for all adults. The request to the US Food and Drug Administration (FDA) would "allow for a fourth dose of our #COVID19 vaccine in adults 18…

Asharq Al-Awsat

Moderna seeks emergency authorisation for second Covid booster in US

Moderna is seeking emergency use authorisation from US regulators for its second dose of a Covid-19 vaccine booster shot.

Evening Standard

Moderna requests FDA approval for fourth COVID shot for adults

Moderna Inc. has filed for U.S. regulatory clearance of a second COVID-19 booster shot for all adults, covering significantly more people than Pfizer Inc. and BioNTech SE’s request earlier this week for a more limited emergency authorization for those over 65.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

Moderna asks FDA to authorize additional booster shot for all adults

The request is much broader than Pfizer's, which sought to authorize a second booster for people over 65.

Axios

Moderna seeks FDA authorization for 4th dose of COVID shot

Drugmaker Moderna has asked the Food and Drug Administration to authorize a fourth shot of its COVID-19 vaccine as a booster dose for all adults

The Independent UK

Health Canada Approves Moderna's COVID-19 Vaccine For Kids Aged 6-11 Years

Health Canada has approved Moderna Inc's (NASDAQ:MRNA) mRNA COVID-19 vaccine, Spikevax, two-dose series of 50 µg per dose to prevent COVID-19 in children aged six to11 years. The announcement follows the recent authorization of the Company's COVID-19 vaccine in the same age group in both Australia and the European Union. "Health Canada was…

Benzinga

Alnylam Hits Pfizer, Moderna With Patent Infringement Suits

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has filed separate lawsuits in the Delaware federal court against Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA), seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Alnylam said it was seeking compensation for the use of its lipid nanoparticles (LNP) technology that carries and delivers…

Benzinga

Here's Why Moderna Shares Are Rising

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 7.0% at $158.42. The company announced today it has reached an agreement with Japan to supply an additional 70 million doses of its COVID-19 booster vaccine.

Benzinga

Psyched: Albert Labs Goes Public, Ex-Moderna Executive Joins MAPS, Novamind and Usona Join For Phase 2 Psilocybin Trial

A new company has entered the public psychedelic markets, with an alternative drug-to-market approach. Using Real World Evidence trials, Albert Labs is expecting to legally provide psilocybin to patients in the UK much earlier than companies working with to get FDA approval.

Benzinga

Moderna Moves Forward With Second HIV Vaccine Trial

Moderna Inc (NASDAQ:MRNA) has dosed the first participant in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574). The open-label, multicenter, randomized Phase 1 trial (HVTN 302) is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines. The primary hypothesis is that the soluble…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What Are Whales Doing With Moderna

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 59 strange trades.

Benzinga

Here's Why Moderna Shares Are Rising On Monday

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 18.9% at $164.27 after the company announced the first participant has been dosed in a clinical trial of an experimental HIV trimer mRNA vaccine.

The Conversation

How drug companies are sidestepping the WHO's technology transfer hub in Africa

Pharmaceutical company Moderna announced on 7 March 2022 that it would develop a site in Kenya to manufacture COVID-19 vaccines. The company holds much of the key intellectual property relating to the messenger RNA (mRNA) vaccines. Due to their higher efficacy, mRNA vaccines are the preferred option in developed countries.…

The Guardian - UK

Moderna co-founder Robert Langer: ‘I wanted to use my chemical engineering to help people’

The celebrated US scientist and inventor on not being in it for the money, why diversity improves problem-solving, and his dedication to exercising

Get all your
news in one place.

100's of premium titles.
One news app.

ABC News

University of Queensland researchers partner with Moderna to create fast-tracked, potentially 'game-changing' vaccines

Queensland researchers are set to partner with biotechnology company Moderna to fast-track the development of vaccines against some of the world's biggest health threats.

Benzinga

Moderna Starts Dosing In Mid-Stage Omicron-Specific Bivalent Booster Candidate

Moderna Inc (NASDAQ: MRNA) has

Tribune News Service

Vacunados con J&J, reforzados con ARNm, y pensando en la tercera dosis

Sí, todos estamos agotados por la pandemia de covid. Desconcertados por los constantes cambios en la ciencia y en las directrices. Preocupados por la sucesión de nuevas y temibles variantes, cada una con su propio nombre, como los huracanes.

Benzinga

Check Out What Whales Are Doing With MRNA

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 40 strange trades.

Benzinga

Chart Wars: Between Moderna And Novavax, Which COVID Stock Will Soar Higher?

Moderna, Inc (NASDAQ: MRNA) and Novavax, Inc (NASDAQ: NVAX) were trading up over 10% and 8%, respectively, at one point on Wednesday, boosted by the S&P 500’s almost 2.6% intraday gain.

Benzinga

'This Stock Could Easily Go To $200': Why Josh Brown Bought Moderna Shares

Ritholtz Wealth Management's Josh Brown has managed to successfully catch another falling knife — at least short term.

Benzinga

Former Moderna Vice President Joins Psychedelics Company In Phase 3 Trials For Ecstasy

Michael Mullette, a former Moderna (NASDAQ:MNRA) vice president is taking a senior leadership position in the MAPS Public Benefit Corporation, a biotech company in the psychedelics sector. The MAPS PCB is a for-profit company wholly owned by the Multidisciplinary Association for Psychedelic Studies, a nonprofit founded in 1986 to advance patient…

1 … 29 30 31 32

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

338 stories

Centers for Disease Control and Prevention

University of Queensland

113 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.